Shifting paradigms: biopharmaceuticals versus low molecular weight drugs

Biosimilares/Investigación | Posted 30/07/2009 post-comment0 Post your comment

Biopharmaceuticals are pharmaceutical products consisting of (glyco)proteins. Nowadays a substantial part of the FDA-approved drugs belong to this class of drugs.

According to Professor Daan Crommelin et al. of the Utrecht Institute for Pharmaceutical Sciences at Utrecht and OctoPlus at Leiden, The Netherlands, biopharmaceuticals deserve special attention as they have a number of characteristics that set them aside from low molecular weight drugs.

 

Their activity depends on their complicated shape based on secondary, tertiary and (sometimes) quaternary structures. These structures cannot be fully defined with our present set of analytical techniques and approaches for potency testing. They are often the same as (or closely resemble) endogenous proteins. This means that in safety testing and clinical test programmes questions have to be addressed regarding species specific responses, selection of dosing schedules and route of administration, and the possible occurrence of immunogenicity. As the conformational structure of a protein is easily disturbed, formulation and handling of biopharmaceuticals needs special attention in order to optimise the therapeutic effect and minimise adverse reaction, amongst which immune responses.

 

The issue of biogenerics is gaining more and more interest and different critical elements in the development of biogenerics are touched upon.

 

They conclude that biopharmaceuticals cannot be characterised fully in terms of their structure like low molecular weight drugs. The performance of biopharmaceuticals relies on strict production protocols and close monitoring of their activity in the clinical situation.

Source: Int J Pharm. 2003;266:3-16.

comment icon Comments (0)
Post your comment
Related content
Advances for Samsung Bioepis’ eculizumab and trastuzumab biosimilars
Turkey 2016 COVER V16E31DG
Biosimilares/Investigación Posted 26/11/2021
Biosimilar mAb development – quality similarity considerations
Quality, similarity and safety V13D12
Biosimilares/Investigación Posted 26/11/2021
Regulación del registro de medicamentos biológicos en América Latina
AA010962
Biosimilares/Investigación Posted 19/11/2021
Biosimilars: Promises made. Promises kept?
ST002293
Biosimilares/Investigación Posted 19/11/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010